A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study
| Autor: | Christoph Tinchon, Shanow Uthman, Thamer Sliwa, Wolfgang R. Sperr, Clemens Dormann, Stefan Schmidt, Peter Valent, Sonja Burgstaller, Veronika Buxhofer-Ausch, Richard Greil, Andreas L. Petzer, Niklas Muenchmeier, Alois Lang, Albert Wölfler, Petra Pichler, Florian Goebel |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent medicine.drug_class Dasatinib Antineoplastic Agents Retrospective evaluation Chronic myeloiud leukemia Tyrosine-kinase inhibitor law.invention 03 medical and health sciences Young Adult 0302 clinical medicine Randomized controlled trial law Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Chronic phase 030304 developmental biology Aged Retrospective Studies Aged 80 and over Tyrosine kinase inhibitors 0303 health sciences business.industry Myeloid leukemia Imatinib General Medicine Middle Aged Clinical trial Treatment Outcome Nilotinib 030220 oncology & carcinogenesis Austria Leukemia Myeloid Chronic-Phase Clinical routine Female Original Article business Bosutinib medicine.drug |
| Zdroj: | Wiener Klinische Wochenschrift |
| ISSN: | 1613-7671 |
| Popis: | Summary Background Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML) showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an improved long-term survival and progression-free survival. This study assessed whether patients achieving early treatment response (ETR; partial cytogenetic response or BCR-ABL1 mRNA ≤10% at 3 months) in daily practice also have a long-term survival benefit. Methods The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-EFECT), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clinical practice. The primary aim was to assess the 5‑year overall survival rate. Results Of the 211 patients from 12 centers across Austria (January 2004–May 2010), 176 (median age, 56 years) were included in the analysis. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR− group). The ETR+ group had higher 5‑year overall survival (92.5% vs. 77.5%, P = 0.018) and progression-free survival (95.6% vs. 87.5%, P = 0.06) rates compared with the ETR− group. As expected, more patients in the ETR− group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib). Conclusion The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clinical routine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink